In a cohort of 142 adults with newly diagnosed ALL, surface CD22 (sCD22) was present on >90% of blasts in 55% of patients, on 51-90% of blasts in 16% of patients, on 11-50% of blasts in 14% of patients, and on 0-10% of blasts in 4% of patients (11). The gene discussed is CD22; the disease is acute lymphoblastic leukemia.